Stablecoin Development (SDEV) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Telomir Pharmaceuticals (TELO) has outperformed Stablecoin Development (SDEV) over the past year, losing 42.0% versus a loss of 76.1%. Telomir Pharmaceuticals is the larger company by market cap ($82.5 million vs $79.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDEV | TELO |
|---|---|---|
| Share price | $1.54 | $1.12 |
| Market cap | $79.70M | $82.45M |
| 1-day change | -22.61% | -2.61% |
| YTD return | -94.54% | -15.79% |
| 1-year return | -76.12% | -41.97% |
| 5-year return | -99.95% | — |
| EPS (TTM) | $-21.13 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.75 | $1.75 |
| 52-week low | $0.78 | $0.888 |
| Distance from 52-week high | -98.46% | -36.00% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +257.14% |
| Average volume | 11.99M | 98.53K |
| Shares outstanding | 51.75M | 73.62M |
| Employees | 2 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TELO has outperformed SDEV by 34.2 percentage points over the past year.
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
SDEV vs TELO FAQ
Which is bigger, Stablecoin Development or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $82.45M compared with $79.70M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, SDEV or TELO?
TELO returned -41.97% over the past 12 months, compared with -76.12% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Stablecoin Development and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.